You are here: Industry Insights > CRISPR

News List

EMA PRIME status granted for Vertex, CRISPR Therapeutics’ gene therapy CTX001 pharmatimes
April 29, 2021
Vertex Pharmaceuticals and CRISPR Therapeutics’ gene therapy CTX001 has been granted a Priority Medicines (PRIME) designation from the European Medicines Agency (EMA).
CRISPR therapies could be one of the most transformative in human history, says GlobalData europeanpharmaceuticalreview
March 17, 2021
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.
CRISPR-based cancer therapies likely to be a disruptive technology in healthcare: GlobalData expresspharma
March 15, 2021
Three leading companies racing to bring CRISPR therapies to the clinic are CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine.
ERS Genomics signs CRISPR license agreement with Otsuka pharmatimes
March 03, 2021
Dublin-headquartered biotech company ERS Genomics has signed a license agreement with Otsuka for access to CRISPR gene editing technology.
DECODR app identifies unintentional DNA mutations from CRISPR gene therapies europeanpharmaceuticalreview
February 24, 2021
The DECODR app was developed to accelerate the development of CRISPR gene therapies, producing similar data as deep sequencing processes in a shorter timeframe and at less cost.
ERS Genomics, ZeClinics Sign CRISPR/Cas9 License Agreement americanpharmaceuticalreview
February 19, 2021
ERS Genomics and ZeClinics announced a non-exclusive license agreement granting ZeClinics access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
Tel Aviv University develops novel lipid nanoparticle-based delivery system to destroy cancer cells expresspharma
January 05, 2021
The system, called CRISPR-LNPs, carries a genetic messenger (messenger RNA), which encodes for the CRISPR enzyme Cas9 that acts as molecular scissors that cut the cells’ DNA.
PerkinElmer to Acquire Cell Engineering Company Horizon Discovery americanpharmaceuticalreview
November 06, 2020
PerkinElmer and Horizon Discovery Group have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire Horizon for approximately $383 million (£296 million).
PerkinElmer to Acquire Horizon Discovery americanpharmaceuticalreview
November 04, 2020
PerkinElmer and Horizon Discovery Group have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire Horizon for approximately $383 million.
Scribe Therapeutics, Biogen collaborate to develop CRISPR-based genetic medicines pharmaceutical-business-review
October 10, 2020
Molecular engineering company Scribe Therapeutics has entered into a research collaboration with Biogen for the development of CRISPR-based genetic medicines for neurological diseases.

Previous page 1 2 3 4 5 6 7 8 Next page